stockrow
Saturday 7 November 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
0.85
0.00
0.00%
Follow MLEC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Dec ’25 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 1 | 6 | 334 | 8 | +1,820.0% | 9 | — | — | (97.4%) | |
| Gross margin, % | — | — | — | — | — | — | — | (15.83) | 3,324.51 | 39.02 | 2,373.25 | +54.9 pt | ||||||
| EBT | — | — | — | — | 0 | 0 | (5) | (52) | (28) | (170) | (28) | +557.8% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | (5,748.44) | (497.02) | (50.96) | (360.30) | (51.0) pt | ||||||
| Net income | — | 0 | — | — | 0 | 0 | (5) | (52) | (7) | (177) | 85 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 3.94 | 22.28 | 774.28 | 30.14 | n/m | |||||
| Earnings | — | — | — | — | (0.67) | (3.96) | (21.89) | (224.89) | (28.96) | (258.69) | (32.49) | +229.3% | ||||||
| Cash flow | — | — | — | — | (0.43) | (38.61) | (9.12) | (32.67) | 156.68 | 8.44 | 0.00 | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.78) | (97.79) | (33.02) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.43) | (38.61) | (9.12) | (33.45) | 58.89 | (24.58) | 0.00 | +125.1% | ||||||
| Book value | — | — | — | — | 0.60 | (132.67) | 7.76 | 43.96 | 990.23 | (192.34) | 0.00 | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +83.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 7.51 | 3.14 | 0.03 | 3.5 | ||||||
| P/B | — | — | — | — | — | — | — | 13.89 | 0.17 | 8.78 | 0.01 | 7.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 75.61 | 5.69 | 8.37 | 27.1 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (18.67) | 28.92 | 2.46 | 3.57 | 4.2 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (2) | (8) | 40 | 4 | 45 | n/m | |||||
| Capex | — | — | — | — | 0 | — | — | 0 | (25) | (14) | (26) | n/m | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | (2) | (8) | 15 | (11) | 18 | +313.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (1) | (3) | (7) | 11 | (205) | (53) | n/m | |||||
| Net debt | — | — | — | — | 0 | 0 | (1) | 0 | 383 | 238 | 65 | +357.3% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (3) | 2 | 10 | 250 | (83) | 15 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (4.46) | (0.14) | (6.29) | (348.24) | (1.50) | (19.31) | 0.00 | (14.8) pt | |||||
| ROIC | — | — | — | — | (6.57) | 0.00 | (436.89) | (41.93) | 1.90 | (42.03) | 0.00 | (35.5) pt | ||||||
| ROE | — | — | — | — | (111.29) | 5.99 | 587.91 | (884.51) | (5.62) | (133.38) | 0.00 | (22.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 4 | 4 | — | 45 | 52 | 103 | — | +91.5% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | — | 0.02 | 0.11 | 3.24 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2025 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026
Moolec Science SA vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| SPRC SciSparc Ltd. | $880.0K | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $830.0K | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MLEC Moolec Science SA | $620.0K | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | |
| CDT CDT Equity Inc. | $390.0K | — (loss-making) | — | — | n/m | +78.92% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $915.0K | — | — | — | — | +11.91% | 25.80% | 0.00% |